Recent Finacing
Recent Raise
Alentis Therapeutics is a clinical-stage biotech developing CLDN1-targeting monoclonal antibodies, ADCs and bi‑specific antibodies for organ fibrosis and CLDN1‑positive solid tumors, with R&D in Strasbourg and HQ in Basel.
